2PU.F PULMATRIX INC. DL-0001
- Market cap
- EUR 4.10M
- P/E
- -
- P/B
- 2.87x
- ROE
- -172.7%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.
Is 2PU.F undervalued?
Graham numberThe Graham number of PULMATRIX INC. DL-0001 cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
PULMATRIX INC. DL-0001 fundamental analysis
No fundamental analysis for PULMATRIX INC. DL-0001 yet.
PULMATRIX INC. DL-0001 stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About PULMATRIX INC. DL-0001
Pulmatrix, Inc., a biopharmaceutical company, focused on development of novel inhaled therapeutic products to prevent and treat migraine and respiratory diseases with unmet medical needs in the United States. The company offers iSPERSE, an engineered dry powder delivery platform, which enables delivery of small or large molecule drugs to the lungs by inhalation for local or systemic applications. It engages in developing PUR1800, a narrow spectrum kinase inhibitor completed …
Full company profilePULMATRIX INC. DL-0001 financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 2 quarters up to Jun 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
PULMATRIX INC. DL-0001 annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|
| Income Statement | ||||||
| Revenue | 5.17M | 6.07M | 7.30M | 7.81M | 0.00 | 0.00 |
| Operating Income | -16.6M | -18.9M | -14.7M | -7.15M | -5.17M | -4.68M |
| EBITDA | - | -17.4M | -13.3M | -6.71M | -5.17M | -4.68M |
| Net Income | -20.2M | -18.8M | -14.1M | -9.56M | -5.16M | -4.42M |
| EPS | -6.26 | -5.18 | -3.87 | -2.62 | -1.41 | -1.21 |
| Balance Sheet | ||||||
| Total Assets | 58.8M | 41.0M | 34.0M | 9.94M | 4.14M | 3.25M |
| Total Liabilities | 11.4M | 9.84M | 16.0M | 996K | 329K | 689K |
| Shareholders' Equity | 47.4M | 31.1M | 18.0M | 8.95M | 3.81M | 2.56M |
| Cash & Short-term Investments | 53.8M | 35.6M | 19.2M | 9.52M | 4.09M | 2.17M |
| Cash Flow | ||||||
| Operating Cash Flow | -19.7M | -19.4M | -16.0M | -10.7M | -5.43M | -4.35M |
| Capital Expenditure | 144K | 86.0K | 676K | 398K | 0.00 | 0.00 |
| Free Cash Flow | -19.9M | -19.4M | -16.7M | -11.1M | -5.43M | -4.35M |
| Ratios | ||||||
| ROE | -42.5% | -60.5% | -78.5% | -106.8% | -135.5% | -172.7% |
| ROA | -34.3% | -46.0% | -41.6% | -96.1% | -124.7% | -136.0% |
| Net Profit Margin | -390.2% | -310.3% | -193.5% | -122.5% | - | - |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
PULMATRIX INC. DL-0001 dividends
PULMATRIX INC. DL-0001 has not paid dividends in the last 7 fiscal years.
Last stock split: 1:20 on Mar 1, 2022.
Who owns PULMATRIX INC. DL-0001
- Insiders 0.78%
- Institutions 9.11%
- Public & others 90.11%
- Shares outstanding 3.65M
- Free float 3.65M
PULMATRIX INC. DL-0001 company profile
- Company name
- PULMATRIX INC. DL-0001
- Ticker
- 2PU.F
- Exchange
- Frankfurt Exchange
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 2
- Fiscal year end
- December
- Address
- 945 Concord Street, Framingham, MA, United States, 01701
- Phone
- 888 355 4440
- Website
- pulmatrix.com
About PULMATRIX INC. DL-0001
Pulmatrix, Inc., a biopharmaceutical company, focused on development of novel inhaled therapeutic products to prevent and treat migraine and respiratory diseases with unmet medical needs in the United States. The company offers iSPERSE, an engineered dry powder delivery platform, which enables delivery of small or large molecule drugs to the lungs by inhalation for local or systemic applications. It engages in developing PUR1800, a narrow spectrum kinase inhibitor completed Phase 1b clinical trials for the treatment of acute exacerbations in chronic obstructive pulmonary disease; PUR1900 for the treatment of allergic bronchopulmonary aspergillosis in patients with asthma and cystic fibrosis; and PUR3100, an iSPERSE formulation of dihydroergotamine which is in Phase 1 for the treatment of acute migraine. It has a license agreement with RespiVert Ltd. for access to a portfolio of kinase inhibitor compounds. The company was founded in 2003 and is headquartered in Framingham, Massachusetts.
PULMATRIX INC. DL-0001 management
2- Mr. Peter Ludlum CMA, MBAInterim CEO & Interim CFO · born 1955
- Dr. Alexander M. Klibanov Ph.D.Founder · born 1950